Pro-Pharmaceuticals, Inc. Announces Dosing Of Patients With DAVANAT(R) In Phase II, First Line, Advanced Biliary Cancer Clinical Trial
NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex:PRW), a developer of novel carbohydrate compounds, today announced the dosing of patients in its Phase II, first line, biliary cancer trial. The Phase II trial is an open-label, multi-center trial of DAVANAT® with 5-Fluorouracil (5-FU) to treat patients with advanced bile duct and gall bladder cancer.